Proteasome inhibition in multiple myeloma
- 31 July 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (11) , 1623-1639
- https://doi.org/10.1016/j.ejca.2006.02.015
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myelomaBlood, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- Bortezomib is an efficient agent in plasma cell leukemiasInternational Journal of Cancer, 2004
- Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administrationZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- A review of the proteasome inhibitor bortezomib in multiple myelomaExpert Opinion on Pharmacotherapy, 2004
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003
- Ubiquitin Protein Ligase Activity of IAPs and Their Degradation in Proteasomes in Response to Apoptotic StimuliScience, 2000
- The human F box protein β-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-cateninOncogene, 1999